On March 14, 2023 Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, reported that it will present multiple oral and poster presentations showcasing the performance of its next-generation liquid biopsy platform at the American Association for Cancer Research (AACR) (Free AACR Whitepaper)’s 2023 annual meeting next month (Press release, Delfi Diagnostics, MAR 14, 2023, View Source [SID1234628713]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations from Delfi and other independent researchers using the DELFI platform will provide updates on Delfi’s lung cancer screening clinical trials, describe the DELFI platform’s ability to detect early stage ovarian cancer, and detail how it performs in monitoring the progress of metastatic colorectal cancer patients on chemotherapy.

"We’re excited to present updates on L101, and CASCADE-Lung, our clinical trials evaluating Delfi’s test for lung cancer screening, as well as new data showing how the Delfi platform performs in other applications, including monitoring," said Delfi President and Chief Operating Officer Jenn Buechel "Taken together, these studies begin to demonstrate the wide range of applications Delfi’s high-performing, affordable platform is capable of delivering."

Details of the presentations appear below:

Oral Presentations:

Title: Prospective evaluation of cell-free DNA fragmentomes for lung cancer detection
Session Title: Behavioral and Biological Opportunities to Improve Cancer Prevention, Early Detection, and Disparities
Session Date/Time: 4/18/23 2:30 PM – 4:30 PM
Abstract Number: 5766

Title: Cell-free DNA fragmentation profiling for monitoring therapeutic response in metastatic colorectal cancer
Session Title: Increasing the Clinical Utility of Cell-Free DNA Testing
Session Date/Time: 4/18/23 2023 2:30 PM – 4:30 PM
Abstract Number: 5714

Poster Presentations:

Title: Early detection of ovarian cancer using cell-free DNA fragmentomes
Session Title: Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment
Session Date and Time: 4/16/23 1:30 PM – 5:00 PM
Location: Section 28
Poster Board Number: 15
Abstract Number: 773

Title: CASCADE-LUNG: Validation of a blood-based assay that evaluates cell-free DNA fragmentation patterns to detect lung cancer
Session Title: Phase II and Phase III Clinical Trials in Progress
Session Date and Time: 4/17/23 9:00 AM – 12:30 PM
Location: Section 46
Poster Board Number: 26
Abstract Number: CT068